987 results on '"Ansell, Jack"'
Search Results
2. Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review
3. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
4. Outcomes of a proactive first responder system for out-of-hospital cardiac arrests
5. Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
6. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
7. Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic
8. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
9. Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
10. Disease understanding in patients newly diagnosed with atrial fibrillation
11. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
12. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
13. Securing administrative leadership commitment for anticoagulation stewardship programs
14. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
15. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants
16. Anticoagulants and Treatment of Venous Thromboembolism
17. Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: a Retrospective Claims-Based Analysis
18. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
19. Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation
20. Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry
21. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
22. Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition
23. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation
24. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
25. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
26. Prevention of Venous Thromboembolism
27. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II])
28. Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation
29. Contributors
30. Outpatient Oral Anticoagulant Therapy
31. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry
32. Anticoagulants and Treatment of Venous Thromboembolism
33. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease
34. North American Thrombosis Forum, AF Action Initiative Consensus Document
35. Impact of Hospital-based Multidisciplinary Anticoagulation Stewardship Programs
36. Reversal of Direct Oral Anticoagulants: Meeting a Need & Filling a Gap
37. Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review
38. Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006–2011
39. Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease
40. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
41. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
42. Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.
43. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
44. Abstract 13544: Race, Ethnicity and Use of Non-Vitamin K Oral Anticoagulants in Patients With AF: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
45. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation)
46. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options
47. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants
48. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
49. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
50. Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.